Adenovirus Type 4 and Type 7 Vaccine Description 2022
Adenovirus Type 4 and Type 7 Vaccine is a live, oral vaccine that contains viable, selected strains of human adenovirus Type 4 and human adenovirus Type 7 prepared in human-diploid fibroblast cell cultures (strain WI-38). The virus strains have not been attenuated.
The cells are grown, and the virus growth is maintained in Dulbecco’s Modified Eagle’s Medium, fetal bovine serum, and sodium bicarbonate. The virus is harvested, freed of particulate cellular material by filtration, formulated, and dried by lyophilization. The dried virus material includes monosodium glutamate, sucrose, D-mannose, D-fructose, dextrose, human serum albumin, potassium phosphate, and plasdone C.
The U.S. FDA-approved vaccine comprises two tablets (one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7) designed to pass intact through the stomach and release the live virus in the intestine. On January 8, 2022, the U.S. CDC updated the Adenovirus VIS.
Bar Labs, Inc. - Teva Pharmaceutical Industries Ltd. - STN: BL 125296/82
Adenovirus Type 4 and Type 7 Indication
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral is a vaccine indicated for active immunization to prevent febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7. The vaccine is only approved in the U.S. military populations 17 through 50 years of age.
Adenovirus Type 4 and Type 7 Dosage
A single vaccine dose is administered orally as two tablets: one tablet of Adenovirus Type 4 and one tablet of Adenovirus Type 7. The tablets should be swallowed whole, without chewing, to avoid releasing the virus in the upper respiratory tract. Postpone administration to individuals with vomiting and/or diarrhea because the vaccine's effectiveness depends upon the multiplication of orally administered live adenovirus within the intestinal tract.
At least 52 immunologically distinct serotypes of adenoviruses can cause human infections. Adenoviruses are unusually stable to chemical and physical agents and varied pH, thus allowing for prolonged survival outside of the body. In the United States, adenovirus serotypes 4 and 7 most commonly cause respiratory illness.
Adenovirus Type 4 and Type 7 News 2005 - 2022
April 28, 2022 - The ECDC published a Risk Assessment - Increase in severe acute hepatitis cases of unknown aetiology in children.
April 25, 2022 - Regular UKHSA updates on the ongoing investigation into higher than usual rates of liver inflammation (hepatitis) in children across the UK.
April 21, 2022 - The U.S. CDC issued a nationwide health alert notifying clinicians and public health authorities about a cluster of children identified with hepatitis and adenovirus infections.
July 23, 2020 - Study: Live Oral Adenovirus Type 4 and Type 7 Vaccine Induces Durable Antibody Response. This investigation provided strong evidence that the live oral AdV-4 and AdV-7 vaccine-induced long-term immunity protects from AdV-4 and AdV-7 infections.
October 15, 2019 - The U.S. FDA updated the BLA 125296 for Barr Labs, Inc.
July 2005 - As a study conclusion, this new approach extends the use of adenovirus vectors and simplifies acute hepatitis research.